GSE223313 naringenin 1 v 2 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE223313_naringenin_1_v_2_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE223313_naringenin_1_v_2_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE223313_naringenin_1_v_2_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE223313_naringenin_1_v_2_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

Rho GTPase activating protein 23

Gene

double homeobox A pseudogene 8

Gene

small nucleolar RNA host gene 7

Gene

HOXA transcript antisense RNA, myeloid-specific 1

Gene

uncharacterized LOC339260

Gene

MIR210 host gene

Gene

long intergenic non-protein coding RNA 1133

Gene

notch 2 N-terminal like R

Gene

family with sequence similarity 66 member B

Gene

MYC inducible lncRNA inactivating p53

  • Gene

    Rho GTPase activating protein 23


  • Gene

    double homeobox A pseudogene 8


  • Gene

    small nucleolar RNA host gene 7


  • Gene

    HOXA transcript antisense RNA, myeloid-specific 1


  • Gene

    uncharacterized LOC339260



  • Gene

    long intergenic non-protein coding RNA 1133


  • Gene

    notch 2 N-terminal like R


  • Gene

    family with sequence similarity 66 member B


  • Gene

    MYC inducible lncRNA inactivating p53

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.